Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer

(2010) R. B. Costa et al.   ANNALS OF ONCOLOGY

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

(2010) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY

How Does Socioeconomic Development Affect Risk of Mortality? An Age-Period-Cohort Analysis From a Recently Transitioned Population in China

(2009) R. Y. Chung et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?

(2009) Donna Rowen et al.   Health and Quality of Life Outcomes

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review

(2008) Yolanda Madarnas et al.   CANCER TREATMENT REVIEWS